SCHEMBL4958208

SCHEMBL4958208

O=C(Nc1nc2c(s1)CCCc1ccccc1-2)c1cnccc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.54
KMT2A Q03164 6/20 0.53
MAPT P10636 6/20 0.53
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
LMNA P02545 5/20 0.53
MEN1 O00255 5/20 0.53
USP2 O75604 1/20 0.53
HTT P42858 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
ALDH1A1 P00352 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HSD17B10 Q99714 1/20 0.53
XIAP P98170 1/20 0.49
ALOX5 P09917 1/20 0.48
KDM4E B2RXH2 3/20 0.45
HPGD P15428 2/20 0.45
THRB P10828 2/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4957466 0.94 POLB (0.61) POLBKMT2AMAPTNPC1RAB9A
SCHEMBL4960420 0.84 MAPT (0.64) POLBKMT2AMAPTNPC1RAB9A
SCHEMBL4957325 0.78 MAPT (0.71) POLBKMT2AMAPTNPC1RAB9A
SCHEMBL4958307 0.78 MAPT (0.71) KMT2AMAPTNPC1RAB9ALMNA
SCHEMBL4958817 0.77 MAPT (0.52) KMT2AMAPTNPC1RAB9ALMNA
SCHEMBL4965626 0.76 MAPT (0.59) POLBKMT2AMAPTNPC1RAB9A
SCHEMBL14276660 0.75 KMT2A (0.65) POLBKMT2AMAPTNPC1RAB9A
SCHEMBL14276667 0.75 KMT2A (0.65) POLBKMT2AMAPTNPC1RAB9A
SCHEMBL30953826 0.73 POLB (0.55) POLBKMT2AMAPTNPC1RAB9A
SCHEMBL14276658 0.72 ALOX5 (0.60) POLBKMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407977-B2 Substituted N-acyl-2-aminothiazoles HOFFMAN-LA ROCHE INC. (US) 2008-08-05 US claimed
EP-1791822-A1 SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES F.HOFFMANN-LA ROCHE AG (CH) 2007-06-06 EP claimed
US-20060030589-A1 Substituted N-acyl-2-aminothiazoles HOFFMANN-LA ROCHE INC. 2006-02-09 US claimed
WO-2006013054-A1 SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2006-02-09 WO claimed
US-7407977-B2 Substituted N-acyl-2-aminothiazoles HOFFMAN-LA ROCHE INC. (US) 2008-08-05 US disclosed
EP-1791822-A1 SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES F.HOFFMANN-LA ROCHE AG (CH) 2007-06-06 EP disclosed
US-20060030589-A1 Substituted N-acyl-2-aminothiazoles HOFFMANN-LA ROCHE INC. 2006-02-09 US disclosed
WO-2006013054-A1 SUBSTITUTED N-ACYL-2-AMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030589-A1 Substituted N-acyl-2-aminothiazoles SLC5A2, ABAT, AGTR2 POLB 3667/4885KMT2A 1497/4885MAPT 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.